Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD (Q33595182)

28 July 2017

title

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD (English)

1 reference

28 July 2017

A Pielen

6

0 references

author name string

C Ehlken

1

1 reference

28 July 2017

S Jungmann

2

1 reference

28 July 2017

D Böhringer

3

1 reference

28 July 2017

H T Agostini

4

1 reference

28 July 2017

B Junker

5

1 reference

28 July 2017

publication date

11 April 2014

1 reference

28 July 2017

1 reference

28 July 2017

volume

28

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

538-545

1 reference

Current knowledge and trends in age-related macular degeneration: today's and future treatments.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Antivascular endothelial growth factors in age-related macular degeneration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4017123

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038/EYE.2014.64

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038/EYE.2014.64

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038/EYE.2014.64

Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways

21 January 2018

1 reference

12 December 2020

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration

1 reference

12 December 2020

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

1 reference

12 December 2020

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results

1 reference

12 December 2020

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study

1 reference

12 December 2020

Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration

1 reference

12 December 2020

Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration (MERITAGE)

1 reference

12 December 2020

Identifiers

DOI

10.1038/EYE.2014.64

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference